Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
00867 CMS
RTNominal down8.220 -4.320 (-34.450%)
Others

09/05/2018 08:52

CMS (00867) product fails to meet standard

[ET Net News Agency, 9 May 2018] China Medical System (CMS) (00867) said Faron
Pharmaceuticals Ltd announced top line data from its pan-European Phase III INTEREST
trial.
The INTEREST study did not meet the Day 28 (D28) primary efficacy composite endpoint of
ventilator free days and survival with Traumakine treatment.
The INTEREST trial was a Phase III double-blind, randomised, parallel-group comparison
to assess the efficacy and safety of Traumakine (FP-1201-lyo) versus placebo in the
treatment of patients with moderate to severe Acute Respiratory Distress Syndrome (ARDS).
CMS believes that, under the current circumstances, the product will not be able to
obtain the necessary regulatory approval for it to be marketed based on the above results.
While the results of the clinical trial are disappointing, the directors of CMS do not
believe that they have any material impact on the financial results of the Group.
Trading in shares of CMS will be resumed today. (HL)

Remark: Real time quote last updated: 28/03/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.